First Time Loading...

Natco Pharma Ltd
NSE:NATCOPHARM

Watchlist Manager
Natco Pharma Ltd Logo
Natco Pharma Ltd
NSE:NATCOPHARM
Watchlist
Price: 974 INR 0.45% Market Closed
Updated: May 11, 2024
Section:
 

Relative Value

The Relative Value of one NATCOPHARM stock under the Base Case scenario is 1 563.94 INR. Compared to the current market price of 974 INR, Natco Pharma Ltd is Undervalued by 38%.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

NATCOPHARM Relative Value
Base Case
1 563.94 INR
Undervaluation 38%
Relative Value
Price
Worst Case
Base Case
Best Case

Valuation Multiples

4.6
P/S
P/S
Price to Sales
4.6
vs History
66
vs Industry
29
Median 3Y
4.8
Median 5Y
5.3
Industry
2.5
Forward
4.4
More Details
13.7
P/E
P/E
Price to Earnings
13.7
vs History
88
vs Industry
34
Median 3Y
27
Median 5Y
25.3
Industry
23.4
Forward
13.3
More Details
23.3
P/OCF
P/OCF
Price to OCF
23.3
vs History
47
vs Industry
20
Median 3Y
23.6
Median 5Y
23.5
Industry
17.9
More Details
25.2
P/FCFE
P/FCFE
Price to FCFE
25.2
vs History
25
vs Industry
20
Median 3Y
20.3
Median 5Y
-49.5
Industry
24.1
More Details
3.3
P/B
P/B
Price to Book Value
3.3
vs History
36
vs Industry
24
Median 3Y
3.1
Median 5Y
3
Industry
2.1
More Details
4.3
EV/S
EV/S
Enterprise Value to Sales
4.3
vs History
66
vs Industry
29
Median 3Y
4.5
Median 5Y
4.8
Industry
2.6
Forward
4.2
More Details
5.5
EV/GP
EV/GP
Enterprise Value to Gross Profit
5.5
vs History
68
vs Industry
40
Median 3Y
5.8
Median 5Y
6.2
Industry
5.2
More Details
10.4
EV/EBITDA
EV/EBITDA
Enterprise Value to EBITDA
10.4
vs History
87
vs Industry
34
Median 3Y
17.5
Median 5Y
17.5
Industry
13.9
Forward
9.6
More Details
11.6
EV/EBIT
EV/EBIT
Enterprise Value to EBIT
11.6
vs History
92
vs Industry
36
Median 3Y
24
Median 5Y
21.2
Industry
17.5
Forward
10.6
More Details
22
EV/OCF
EV/OCF
Enterprise Value to OCF
22
vs History
50
vs Industry
22
Median 3Y
22.3
Median 5Y
22
Industry
16.4
More Details
30
EV/FCFF
EV/FCFF
Enterprise Value to FCFF
30
vs History
33
vs Industry
16
Median 3Y
16.2
Median 5Y
16.2
Industry
18.1
More Details
3.5
EV/IC
EV/IC
Enterprise Value to IC
3.5
vs History
34
vs Industry
24
Median 3Y
3.2
Median 5Y
3.1
Industry
1.9
More Details

Multiples Across Competitors

NATCOPHARM Competitors Multiples
Natco Pharma Ltd Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
IN
Natco Pharma Ltd
NSE:NATCOPHARM
174.5B INR 4.6 13.7 10.4 11.6
JP
Nichi-Iko Pharmaceutical Co Ltd
TSE:4541
776 550.9T JPY 4 211 733 -5 347 888.9 -5 459 134.4 -5 046 864.6
US
Eli Lilly and Co
NYSE:LLY
722.3B USD 20.1 117.7 57.6 65.6
DK
Novo Nordisk A/S
CSE:NOVO B
3.9T DKK 16.1 44.1 32.9 36.1
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP 578.3 -15 783.5 3 846.3 17 702.3
US
Johnson & Johnson
NYSE:JNJ
360.8B USD 4.2 9.4 11.6 15.1
US
Merck & Co Inc
NYSE:MRK
329.4B USD 5.4 142.8 35.6 58.1
UK
AstraZeneca PLC
LSE:AZN
191.8B GBP 5 37.9 174.6 278.6
CH
Novartis AG
SIX:NOVN
180.6B CHF 3.4 11.4 8.7 12.7
CH
Roche Holding AG
SIX:ROG
179.5B CHF 3.1 15.6 8.9 10.5
US
Pfizer Inc
NYSE:PFE
158.1B USD 2.9 -511.8 12.7 20.2
P/E Multiple
Earnings Growth
IN
Natco Pharma Ltd
NSE:NATCOPHARM
Average P/E: 49.1
13.7
144%
JP
N
Nichi-Iko Pharmaceutical Co Ltd
TSE:4541
Negative Multiple: -5 347 888.9 N/A
US
Eli Lilly and Co
NYSE:LLY
117.7
346%
DK
Novo Nordisk A/S
CSE:NOVO B
44.1
84%
UK
Dechra Pharmaceuticals PLC
LSE:DPH
Negative Multiple: -15 783.5 N/A
US
Johnson & Johnson
NYSE:JNJ
9.4
-20%
US
Merck & Co Inc
NYSE:MRK
142.8
7 454%
UK
AstraZeneca PLC
LSE:AZN
37.9
168%
CH
Novartis AG
SIX:NOVN
11.4
15%
CH
Roche Holding AG
SIX:ROG
15.6
26%
US
Pfizer Inc
NYSE:PFE
Negative Multiple: -511.8
680%

See Also

Summary
NATCOPHARM intrinsic value, competitors valuation, and company profile.
DCF Valuation
NATCOPHARM stock valuation using Discount Cash Flow valuation method.
Relative Valuation
NATCOPHARM stock valuation using valuation multiples.
Wall Street Estimates
NATCOPHARM price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
NATCOPHARM stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
ALPHA SPREAD
Join more than 136,200+ value investors using Alpha Spread
Create a free account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2024 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.